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Abstract
Background In Henoch–Schönlein nephritis (HSN), a risk factor for unfavorable outcome is prolonged proteinuria, but the value
of renal biopsies in prognosis assessment is debatable.
Methods We evaluated serial renal biopsies from 26 HSN patients. Follow-up biopsy occurred at median 2.1 years after
diagnostic biopsy. Patients formed two groups at the follow-up biopsy: patients without proteinuria (group I; n = 11) and with
proteinuria (group II; n = 15). Biopsies underwent evaluation according to three classifications: International Study of Kidney
Disease in Children (ISKDC), Oxford (MEST-C), and semiquantitative classification (SQC) including an activity and chronicity
score. Analysis also included expression of pro-fibrotic (alpha-smooth muscle actin and vimentin) and inflammatory (P-selectin
glycoprotein ligand-1) molecules in the diagnostic biopsy specimens. Definition of unfavorable outcome was active renal disease
or reduced renal function at last follow-up.
Results Between the biopsies, SQC chronicity score increased in 22 (85%) patients, whereas activity score and ISKDC grade
decreased in 21 (81%) and 17 (65%), respectively. Of the MEST-C parameters, endocapillary proliferation (from 83 to 13%; p <
0.001) and crescents (from 63 to 25%; p = 0.022) showed significant reduction, and segmental glomerulosclerosis (from 38 to
79%; p = 0.006) significant increment. These changes occurred similarly in groups I and II. Expression of the pro-fibrotic and
inflammatory molecules showed no clinically significant differences between groups I and II. None in group I and five (33%)
patients in group II had unfavorable outcome (p = 0.053).
Conclusions Our results suggest that follow-up biopsies provide limited additional information to clinical symptoms in HSN outcome
prediction.
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Introduction
The most common vasculitis in children is Henoch–Schönlein
purpura (HSP) [1]. Its typical symptoms manifest in the skin,
gastro-intestinal tract, joints, and kidneys, and the severity of
the renal symptoms determines the long-term outcome. Of
HSP patients, on average, 34% develop renal symptoms [2].
The symptoms are typically self-limiting proteinuria or
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hematuria, or both, but some patients develop severe protein-
uria, and these patients are at greater risk for chronic kidney
disease [3, 4].
For Henoch–Schönlein nephritis (HSN), the most common
histologic classification is from the International Study of
Kidney Disease in Children (ISKDC) [5]. Although it also
considers mesangial proliferation, ISKDC classification is
largely based on the percentage of glomeruli with crescents,
and treatment modality selection is based on ISKDC grade.
The prognostic value of the ISKDC classification is, however,
questionable, giving rise to a need for a new classification [6,
7]. The Oxford classification for IgA nephropathy (IgAN), a
disease with similar renal histology to HSN, appeared in 2009
[8]. The updated version of the Oxford classification (MEST-
C) now considers five histologic parameters: mesangial
hypercellullarity (M), endocapillary proliferation (E), segmen-
tal glomerulosclerosis (S), tubular atrophy and/or interstitial
fibrosis (T), and crescents (C) [9]. However, in pediatric HSN,
the feasibility of MEST-C requires still further research [7].
Furthermore, we recently introduced a semiquantitative clas-
sification (SQC) for histologic evaluation of HSN [10].
In this study, we evaluated ISKDC, SQC, and MEST-C
scores in sequential renal biopsy specimens. Additionally, from
d i a g n o s t i c k i d n e y b i o p s i e s , w e a n a l y z e d
immunohistochemically the expression of pro-fibrotic and in-
flammatory cell markers. Alpha-smooth muscle actin (α-SMA)
and vimentin are pro-fibrotic markers, whereas P-selectin gly-
coprotein ligand-1 (PSGL-1) is a marker for inflammatory cells;
early detection of the processes featuring these markers could
prove important in enabling early treatment before the develop-
ment of fibrosis. The aim of our study was to evaluate the
prognostic value of (1) the ISKDC, SQC, and MEST-C classi-
fications and (2) the expression of pro-fibrotic and inflammatory
markers. Our hypothesis was that expression of these markers in
the diagnostic kidney biopsies correlates with the findings in the
follow-up renal biopsy, and that their expression is higher in
HSN patients than in control samples from normal kidneys.
Materials and methods
Study design
The study comprises 26 childhood-onset (< 17 years) patients
with HSN with an available follow-up renal biopsy specimen
from Oulu University Hospital (1985–2005), Helsinki
University Hospital (2000–2010) and a nationwide study
[11]. A detailed description of the study population exists in
our previous study, which analyzed the role of diagnostic renal
biopsies for predicting outcomes in 53 HSN patients [10].
This study was approved by the ethics committee of
Helsinki University Hospital (164/13/03/03/2016).
Clinical data
Definition of proteinuria was urine protein to creatinine ratio
(UP/C) > 20 g/mol, daily urine protein excretion (dU-Prot) >
200 mg, or a positive urine dipstick test (1+ to 3+). UP/C
values at the time of the renal biopsies were converted into
dU-Prot [12], and values over 40 mg/h/m2 denoted nephrotic-
range proteinuria. Definition of hematuria was > 20 red blood
cells/10E6/L or a positive urine dipstick test (1+ to 3+).
Glomerular filtration rate was estimated (eGFR) with the bed-
side Schwartz equation [13]. Medical records provided data
from the time of the diagnostic and follow-up biopsies and the
last follow-up. Time from the onset of nephritis (proteinuria
and/or hematuria) to renal biopsy and initiation of treatment
was calculated. Patients (n = 2) who had not received immu-
nosuppressive therapy were not included in the treatment de-
lay analyses. Follow-up time was the period from HSP-
diagnosis to the latest follow-up visit or to the start of renal
replacement therapy. Indication for the diagnostic renal biopsy
was either nephrotic-state proteinuria or persistence of pro-
teinuria and/or hematuria up to 6–8 weeks. The 26 patients
formed two groups at follow-up renal biopsy: patients without
proteinuria (group I; n = 11) and with proteinuria (group II; n =
15). Eleven patients had no proteinuria at follow-up biopsy:
nine of them underwent follow-up biopsy as part of a previous
trial in accordance with the study protocol [11], one due to
hematuria, and one for control purposes.
Outcome
Outcome assessment at the last follow-up was as follows:
outcome A (healthy)—no signs of renal disease; outcome B
(minor urinary abnormalities)—UP/C = 20–100 g/mol and/or
microscopic hematuria and/or ongoing ACE-I treatment; out-
come C (active renal disease)—UP/C > 100 g/mol and/or
ongoing immunosuppressive treatment; outcome D (reduced
renal function)—eGFR < 60 mL/min/1.73 m2. Outcomes A +
Bwere categorized as favorable outcome and outcomes C + D
as unfavorable outcome.
Renal biopsy classifications
Renal pathologists blinded to the patients’ medical history re-
evaluated the biopsies with the ISKDC classification, SQC,
and MEST-C. A detailed explanation of SQC parameters ex-
ists in our previous study [10]; the classification is also visible
in online Table S1. Briefly, SQC comprises 14 renal histologic
parameters and has a maximum score of 26 points; it divides
into activity (maximum 9 points) and chronicity indices (max-
imum 16 points). In addition, a tubulointerstitial (including all
active and chronic tubular and interstitial parameters) index
can be calculated (maximum 5 points). The MEST-C scoring
system of the Oxford classification includes five parameters
Pediatr Nephrol (2020) 35:659–668660
and is defined as follows: M (mesangial hypercellularity de-
fined as more than four mesangial cells in any mesangial area)
as M0 (< 50% of glomeruli with mesangial hypercellularity)
or M1 (> 50%); E (endocapillary proliferation) as E0 (absent)
or E1 (present); S (segmental glomerulosclerosis) as S0
(absent) or S1 (present); T (tubular atrophy and/or interstitial
fibrosis) as T0 (0–25% of cortical area affected), T1 (26–
50%), or T2 (> 50%) and C (crescents) as C0 (absent), C1
(at least 1 crescent, but crescents in a maximum of 25% of
glomeruli) or C2 (> 25%). In addition, total MEST-C score
was calculated (sum of all five MEST-C parameters).
Immunohistochemistry and microscopy
Diagnostic renal biopsy specimens, formalin-fixed and paraf-
fin-embedded, were cut into 4–5-μm-thick slices. They
underwent a conventional immunohistochemical staining pro-
cess. Primary antibodies were used against α-SMA (clone
1A4, diluted 1:400, Dako Denmark A/S, Glostrup,
Denmark), vimentin (clone 3B4, 1:200, Dako), and PSGL-1
(sc-13535, 1:500, Santa Cruz Biotechnology, Inc., Dallas, TX,
USA). Eighteen (69%) biopsies were successfully stained
with α-SMA, 19 (73%) with vimentin, and 17 (65%) with
PSGL-1. Negative controls containing no primary antibodies
were incubated in phosphate-buffered saline. Normal kidneys,
originally removed with an intent to use as kidney transplants,
served as control specimens. Supplementary material contains
images (Figures S1–S3) of typical expression of the analyzed
molecules in HSN patients and in control specimens.
The microscopy tool used was Zeiss AX10. Analyses of the
HSN biopsy specimens involved all glomeruli (with × 20 mag-
nification) and as many microscopic fields as possible from the
cortical tubulointerstitium (× 40). Analysis of each control spec-
imen included 30 randomly selected glomeruli (× 20) and 30
randomly selected, non-overlapping tubulointerstitial micro-
scopic fields (× 40). Zeiss Zen software (Carl Zeiss AG,
Oberkochen, Germany) performed calculation of the
tubulointerstial area of positive α-SMA and vimentin staining.
The number of PSGL-1 staining patches was counted from the
tubulointerstitium and glomeruli. In evaluation of the staining
results, scores of all microscopic fields and glomeruli were to-
taled separately for control specimens, group I, and group II. To
assess correlation with staining results and biopsy findings in
HSN patients, mean of the microscopic fields’ affected areas
(α-SMA, vimentin) and the mean number of staining patches
in the tubulointerstitium and glomeruli (PSGL-1) represented the
scores for each patient. Patients’ clinical data was not available
when conducting the immunohistochemical analyses.
Statistical analyses
The statistical analysis software used was IBM SPSS version
22 (IBM Corp, Armonk, NY). Continuous variables are
reported as means and standard deviations (SD) (normal dis-
tribution) or medians and interquartile ranges (IQR) (non-nor-
mal distribution), and analyzed with Student’s t test (normal
distribution) or Mann–Whitney U test (non-normal distribu-
tion). Categorical variables are reported as numbers and per-
centages, and analyzed with Fisher’s exact test. Change in
histologic variables from the diagnostic biopsy to the follow-
up biopsy was analyzed with McNemar test (MEST-C
parameters) or Wilcoxon-signed rank test (SQC parameters).
Spearman rank correlations were calculated between staining
results, biopsy findings, and biopsy delays. Results from lin-
ear regression are reported as regression coefficients (B value)
with 95% confidence intervals. Predictors with p < 0.2 in
univariable analysis were selected to the multivariable analy-
sis. The level of statistical significance was p < 0.05.
Results
Patient characteristics and outcome
Table 1 provides baseline patient characteristics. Patients in
group II were older than those in group 1; no other statistically
significant differences existed between the groups at the time
of the diagnostic renal biopsy. Median time from onset of
nephritis to the diagnostic renal biopsy was 59 (IQR 36–71)
days in patients without proteinuria (group I) and 33 (IQR 19–
60) days in proteinuric patients (group II) (p = 0.17). Median
time from renal biopsy to immunosuppressive treatment was 7
(IQR 4–8) days and 7 (IQR 2–16) days in groups I and II,
respectively (p = 0.94).
Table 2 presents patient characteristics at the follow-up bi-
opsy and at last follow-up. Follow-up biopsy was performed a
median of 2.2 (IQR 2.0–2.3) years after the diagnostic biopsy
in group I and 2.1 (1.7–2.2) years in group II (p = 0.31). At the
follow-up biopsy, plasma creatinine levels were significantly
higher in group II than in group I, but there was no statistically
significant difference in eGFR. Clinical and biopsy character-
istics according to the outcome (favorable/unfavorable) are pre-
sented in the Supplementary material (Table S2). At the follow-
up biopsy, patients with unfavorable outcome had significantly
higher proteinuria than those with favorable outcome (median
dU-Prot 4.7 vs. 0.2 g/day; p < 0.001).
At the last follow-up, patients without proteinuria (group I)
had significantly lower creatinine and higher eGFR than pro-
teinuric patients (group II). Fifteen (58%) patients belonged to
outcome group A, 6 (23%) to outcome group B, 1 (4%) to
outcome group C, and 4 (15%) to outcome group D. Five
patients had unfavorable outcome: one had ongoing cyclospor-
ine A treatment due to persistent proteinuria, one had reduced
renal function (eGFR 37mL/min/1.73m2), two developed end-
stage kidney disease, and one had succumbed due to HSN [14].
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None in group I developed unfavorable outcome compared to
five patients (33%) in group II (p = 0.053).
SQC and ISKDC
In the diagnostic and follow-up biopsies of all 26 patients,
median activity scores were 4 (IQR 2–7) and 2 (IQR 1–2) (p
< 0.001), median chronicity scores 3 (IQR 2–4) and 7 (IQR 5–
9) (p < 0.001), and median tubulointerstitial scores 0 (IQR 0–
1) and 3 (IQR 2–3) (p < 0.001), respectively. Activity scores in
the diagnostic and follow-up biopsy and chronicity score in
the follow-up biopsy were significantly higher in group II than
in group I (Tables 1 and 2). Figure 1 illustrates individually in
each patient the changes in the SQC activity, chronicity, and
tubulointerstitial scores, and in the ISKDC grades between
diagnostic and follow-up biopsy. Between the biopsies, SQC
activity score decreased in 21 (81%) patients and ISKDC
grades in 17 (65%), whereas chronicity score increased in 22
(85%) patients and tubulointerstitial score in 21 (81%).
Changes occurred similarly in groups I and II (Fig. 1). In all
five patients with unfavorable outcome, activity scores
decreased whereas chronicity and tubulointerstitial scores in-
creased (Table S2). SQC activity and chronicity scores in the
follow-up biopsy showed no significant correlation with time
from disease onset to treatment and did not differ significantly
according to the initial treatment (data not shown). In multiple
regression, activity score in the diagnostic biopsy was an in-
dependent predictor of the chronicity score in the follow-up
biopsy (Table 3). Median number of glomeruli per biopsy was
21 (IQR 12–25) in the diagnostic biopsy and 15 (IQR 12–22)
in the follow-up biopsy.
MEST-C
Table 4 showsMEST-C scores in the diagnostic and follow-up
biopsies. Between the biopsies, S1 (from 38 to 79%; p = 0.006)
and T1–2 (from 0 to 13%; p = 0.25) scores increased, whereas
E1 (from 83 to 13%; p < 0.001) and C1–2 (from 63 to 25%; p =
0.022) scores decreased. M1 was similarly present in both bi-
opsies (33%; p > 0.99). Table 4 also reports biopsies where
tubular atrophy and/or interstitial fibrosis (T score) was present,
but for less than 25% of the cortical area (marked as T > 0% in
Table 1 Baseline characteristics at the diagnostic renal biopsy, ISKDC findings of the diagnostic biopsy, and used therapies
All (n = 26) Group I (n = 11) Group II (n = 15) p value
Male, n (%) 17 (65%) 5 (45%) 12 (80%) 0.10
Age (years) 9.8 ± 3.4 7.7 ± 2.6 11.2 ± 3.1 0.006
Plasma creatinine (μmol/L) 52 (45–58) 51 (44–55) 53 (46–62) 0.30
eGFR (mL/min/1.73 m2) 99 (87–109) 90 (87–108) 100 (89–108) 0.80
Plasma albumin (g/L) 29.3 ± 8.8 30.4 ± 8.2 28.7 ± 9.4 0.66
dU-Prota (g/day) 4.8 (1.6–7.7) 3.8 (1.0–5.8) 4.8 (1.8–10.2) 0.50
dU-Prota (mg/h/m2) 140 (69–328) 136 (52–233) 150 (77–332) 0.72
Nephrotic-range proteinuria (> 40 mg/h/m2), n (%) 20 (77%) 8 (73%) 12 (80%) > 0.99
Hematuria, n (%) 26 (100%) 11 (100%) 15 (100%) > 0.99
ISKDC
I
II
IIIa
IIIb
IV
V
0
6
5
12
2
1
0
4
1
6
0
0
0
2
4
6
2
1
SQC activity score 4 (2–7) 4 (1–4) 6 (4–7.5) 0.018
SQC chronicity score 3 (2–4) 3 (1.5–3.5) 3 (2.5–4) 0.37
SQC tubulointerstitial score 0 (0–1) 0 (0–0.5) 0 (0–1) 0.31
IT, n (%) 24 (92%) 9b (82%) 15c (100%) 0.17
ACE-I, n (%) 21 (81%) 8 (73%) 13 (87%) 0.62
Group I represents patients without proteinuria and group II patients with proteinuria at the follow-up biopsy. eGFR, estimated glomerular filtration rate;
dU-Prot, daily urine protein excretion; IT, immunosuppressive therapy; ACE-I, angiotensin-converting enzyme inhibitor
a For one patient in group I proteinuria at the diagnostic renal biopsy was measured only as a negative dipstick test and was not included in the analyses
b Initial immunosuppressive therapies in group I were methylprednisolone pulses (n = 6) and cyclosporine A (n = 3). Two patients had not received
immunosuppressive therapy
c Initial immunosuppressive therapies in group II were methylprednisolone pulses (n = 8), cyclosporine A (n = 4), azathioprine (n = 1), cyclophospha-
mide (n = 1), and oral prednisone (n = 1)
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Table 3). T > 0% score increased from 4 to 67% between the
diagnostic and follow-up biopsy (p < 0.001). Marked differ-
ences between group I and group II occurred especially in the
follow-up biopsies’ presence of C1–2 (0% vs. 40%, p = 0.052)
and E1 (0% vs. 20%, p = 0.27). Baseline characteristics for
patients with and without C1–2 at the follow-up biopsy were:
age 12.1 years (IQR 7.6–14.1) vs. 9.0 years (IQR 7.6–11.8) (p
= 0.31), proteinuria 284 mg/m2/h (IQR 106–336) vs. 131 mg/
m2/h (52–255) (p = 0.35), and eGFR 94 mL/min/1.73 m2 (IQR
85–101) vs. 102 mL/min/1.73 m2 (IQR 89–110) (p = 0.42),
respectively. Initial treatment of patients with C1–2 at the
follow-up biopsy was methylprednisolone pulses (n = 4), cy-
closporine A (n = 1), and cyclophosphamide (n = 1).
Immunohistochemistry
Expression of α-SMA, vimentin, and PSGL-1 was
higher in HSN biopsies than in control specimens
(combined HSN groups I and II vs. controls, p <
0.001 for all markers). Tubulointerstitial scores (α-
SMA, vimentin, PSGL-1) were higher in group I than
in group II (p < 0.001 for all markers) (Fig. 2). In
glomeruli, PSGL-1 expression in groups I and II was
similar (p = 0.85). Table 5 contains correlations between
staining results and SQC activity, chronicity, and
tubulointerstitial indices. α-SMA showed positive corre-
lations with all parameters and significant correlation
with follow-up biopsies’ tubulointerstitial index.
Vimentin showed significant negative correlation with
chronicity and tubulointerstitial index of the follow-up
biopsy. PSGL-1 exhibited no significant correlation with the
SQC indices. No staining showed significant correlation with
the time from the onset of nephritis to the diagnostic renal
biopsy (α-SMA: r = 0.22, p = 0.38; vimentin: r = -0.066, p
= 0.79; PSGL-1 in glomeruli: r = -0.13, p = 0.62; PSGL-1 in
tubulointerstitium: r = 0.065, p = 0.83).
Table 2 Patient characteristics at the follow-up renal biopsy, ISKDC findings of the follow-up biopsy, and outcome at the last follow-up visit
All (n = 26) Group I (n = 11) Group II (n = 15) p value
At the follow-up biopsy
Age (years) 12.6 ± 4.6 11.1 ± 5.4 13.8 ± 3.7 0.14
Plasma creatinine (μmol/L) 58 (41–67) 53 (38–58) 66 (53–74) 0.024
eGFR (mL/min/1.73 m2) 98 (89–121) 103 (96–126) 94 (82–108) 0.069
dU-Prota (g/day) 0.3 (0.1–1.2) 0.10 (0.91–0.11) 0.9 (0.3–3.3) NAb
Hematuria, n (%) 16 (62%) 5 (45%) 11 (73%) 0.23
ISKDC
I
II
IIIa
IIIb
IV
V
1
16
3
4
1
1
1
9
0
1
0
0
0
7
3
3
1
1
SQC activity score 2 (1–2) 1 (1–2) 2 (1–4,5) 0.033
SQC chronicity score 7 (5–9) 6 (3.5–7) 9 (7–10.5) 0.013
SQC tubulointerstitial score 3 (2–3) 3 (1–3) 3 (2–4) 0.096
At the last follow-up
Age (years) 19.1 ± 6.7 16.0 ± 6.5 21.4 ± 5.9 0.035
Follow-up (years) 8.6 (6.4–11.3) 6.8 (6.2–8.2) 9.0 (8.3–12.8) 0.041
Plasma creatinine (μmol/L) 75 (58–87) 58 (51–71) 77 (75–123) 0.003
eGFRc (mL/min/1.73 m2) 86 (73–96) 96 (86–121) 83 (38–86) 0.011
Outcome
A
B
C
D
15
6
1
4
9
2
0
0
6
4
1
4
Group I represents patients without proteinuria and group II patients with proteinuria at the follow-up biopsy. eGFR, estimated glomerular filtration rate;
dU-Prot, daily urine protein excretion; NA, not applicable
a n = 21 (8 in group I and 13 in group II; for 3 patients in group I and 2 patients in group II proteinuria was measured only as a dipstick test or as U-Prot;
these patients were not included in the analysis)
b Group I comprises patients with no proteinuria at the follow-up renal biopsy
c n = 25 (11 in group I and 14 in group II)
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Discussion
The aim of our study was to evaluate the prognostic value of
three histologic classifications: ISKDC, SQC, and MEST-C.
We also evaluated whether pro-fibrotic and inflammatory
markers in diagnostic renal biopsy specimens predicted clini-
cal outcomes and lesions in follow-up renal biopsies. Between
the diagnostic and follow-up biopsy, active changes decreased
and chronic changes increased regardless of the clinical symp-
toms. Nonetheless, patients with proteinuria at the follow-up
biopsy (group II) had higher SQC activity scores in the diag-
nostic biopsy and higher activity and chronicity scores at the
follow-up biopsy than patients without proteinuria (group I).
The studied pro-fibrotic and inflammatory markers were
higher in HSN biopsy specimens than in controls, but showed
no value as predictors of prolonged proteinuria.
We divided the patients according to proteinuria at the
follow-up biopsy, since prolonged proteinuria is associated
with worsened prognosis [15, 16]. In accordance with these
reports, all five patients with poor outcome in our study had
prolonged proteinuria. In most patients, regardless of the pro-
teinuria, activity scores decreased and chronicity scores in-
creased from diagnostic biopsy to follow-up biopsy. This
was also evident in MEST-C scores: between the biopsies
E1 decreased, whereas S1, T1–2, and T > 0% increased.
Regarding these changes in activity and chronicity scores in
serial HSN biopsies, previous studies have shown comparable
results [17–19]. Consistent with the findings of Shin et al.
[17], the follow-up biopsies of 21 patients with favorable out-
come contained chronic histologic changes. This suggests that
even with favorable therapeutic outcome, HSN patients re-
quire long-term follow-up since the increased histological
chronici ty may impact the long-term prognosis .
Furthermore, since most of our patients were treated with im-
munosuppressive drugs and angiotensin-converting enzyme
inhibitors, progression of the chronicity signs can be consid-
ered as an insufficient response to the treatment.
Based on our results, MEST-C parameters in pediatric HSN
seem feasible.MEST-C originates from adult IgAN patient data
and thus some modifications to the classification may prove
necessary for the evaluation of pediatric HSN. For example,
tubulointerstitial lesions of MEST-C (i.e., T1 and 2) in our
cohort were rare. They were, however, more common after
inclusion of biopsies with less than 25% of affected area.
Progression of tubulointerstitial lesions associates with a longer
duration of proteinuria [20], and it could therefore prove
Fig. 1 Changes in the activity (a),
chronicity (b), and
tubulointerstitial scores (c) of the
semiquantitative classification
(SQC), and in the International
Study of Kidney Diseases in
Children classification (ISKDC)
grades (d) between diagnostic and
follow-up biopsy presented indi-
vidually in 26 Henoch–Schönlein
nephritis patients. The number of
patients with decreased activity
score (p = 0.62), decreased
ISKDC grade (p > 0.99), in-
creased chronicity score (p >
0.99), or increased
tubulointerstitial score (p = 0.62)
did not differ between groups I
and II. Numbers in figures denote
the number of patients with simi-
lar change in respective SQC
score or ISKDC grade
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important to consider all lesions affecting the tubulointerstitium
and not only those exceeding 25% of the renal cortex area.
C1–2 were present in both groups’ diagnostic biopsies, but
were only seen in the follow-up biopsies in group II. The
persistence of crescents thus seems to associate with
prolonged proteinuria, supporting results from other studies
that treatment should be commenced before fibrotization of
crescents [19]. Active treatment is also supported by the find-
ing that active lesions in the diagnostic biopsy predicted
chronic lesions in the follow-up biopsy. M1 was similarly
present in both biopsies. Similar results were observed in adult
IgAN patients after a 6-month treatment with mycophenolate
mofetil and prednisone [21]. M1 thus seem not to be a flexible
sign of clinical improvement and may suggest that the under-
lying pathogenetic event is still present. In HSN, the clinical
meaning (and whether they need further therapy) of the per-
sistent M1 and increased S1/T1-2 findings is unknown. It is
possible that the renal damage continues despite minimal clin-
ical signs and that the eGFR has remained stable due to the
insufficient follow-up.
Oxford classification has been validated to predict out-
comes in IgAN, and in a recent study, M1, S1, and T1–2 were
predictive of progression decades after the renal biopsy [22].
Previous studies on the feasibility of MEST-C in pediatric
Table 3 Linear regression results for chronicity score in the follow-up biopsy
Univariable Multivariable
B 95% CI p value B 95% CI p value
Gender (male vs. female) − 0.39 − 3.12 to 2.34 0.77
Age at onset (years) 0.35 − 0.19 to 0.71 0.062 − 0.005 − 0.30 to 0.29 0.97
dU-Prota (mg/h/m2) − 0.004 − 0.014 to 0.005 0.33
eGFRa (mL/min/1.73 m2) − 0.011 − 0.064 to 0.041 0.66
SQC activity scorea 0.94 0.60 to 1.28 < 0.001 0.74 0.34 to 1.12 0.001
SQC chronicity scorea 0.43 − 0.19 to 1.05 0.17 0.42 − 0.032 to 0.88 0.067
M1a 0 − 2.68 to 2.68 > 0.99
E1a − 1.35 − 4.68 to 1.98 0.41
S1a 0.11 − 2.50 to 2.72 0.93
C1–2a 2.38 − 0.008 to 4.76 0.051 0.86 − 1.23 to 2.95 0.40
T1 was not present in the diagnostic biopsies and thus was not included in the analyses. Since crescents are included also in the SQC activity score, we
performed multivariable analysis with age at onset, SQC activity score, and SQC chronicity score (i.e., excluding C1–2 from the analysis). Results did
not markedly change (data not shown). B, regression coefficient; CI, confidence interval; dU-Prot, daily urine protein excretion; eGFR, estimated
glomerular filtration rate; M, mesangial hypercellularity; E, endocapillary proliferation; S, segmental glomeruloscrelosis; T, tubular atrophy and/or
interstitial fibrosis; C, crescents
a At the diagnostic biopsy
Table 4 MEST-C scoring according to the Oxford classification
Diagnostic biopsy Follow-up biopsy
All Group I Group II p value All Group I Group II p value
M1, n (%) 8 (33%) 2 (22%) 6 (40%) 0.66 8 (33%) 2 (22%) 6 (40%) 0.66
E1, n (%) 20 (83%) 7 (78%) 13 (87%) 0.62 3 (13%) 0 3 (20%) 0.27
S1, n (%) 9 (38%) 4 (44%) 5 (33%) 0.68 19 (79%) 6 (67%) 13 (87%) 0.33
T1–2, n (%) 0 0 0 NA 3 (13%) 1 (11%) 2 (13%) > 0.99
T > 0%a, n (%) 1 (4%) 0 1 (7%) > 0.99 16 (67%) 5 (56%) 11 (73%) 0.41
C1, n (%) 9 (38%) 5 (56%) 4 (27%) 0.21 5 (21%) 0 5 (33%) 0.12
C2, n (%) 6 (25%) 0 6 (40%) 0.052 1 (4%) 0 1 (7%) > 0.99
C1–2, n (%) 15 (63%) 5 (56%) 10 (67%) 0.68 6 (25%) 0 6 (40%) 0.052
Total MEST-C score 2.5 (2–3) 2 (2–3) 3 (2–3) 0.39 1 (1–2.5) 1 (1–1) 2 (1–3.5) 0.10
48/52 renal biopsy specimens (combined diagnostic and follow-up renal biopsy) were available for MEST-C analysis. Group I represents patients
without proteinuria and group II patients with proteinuria at the follow-up biopsy. M, mesangial hypercellularity; E, endocapillary proliferation; S,
segmental glomeruloscrelosis; T, tubular atrophy and/or interstitial fibrosis; C, crescents; NA, not applicable
a Comprises patients whose renal biopsies showed tubular atrophy and/or interstitial fibrosis affecting > 0% of the renal cortical area
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Fig. 2 Scores for tubulointerstitial alpha-smooth muscle actin (α-SMA)
(a), vimentin (b), and P-selectin glycoprotein ligand-1 (PSGL-1) (c), as
well as for glomerular PSGL-1 (d), in normal kidney specimens and in
Henoch–Schönlein nephritis patients without proteinuria (group I) and
with proteinuria (group II) at the follow-up renal biopsy. Numbers in
figures denote the total number of microscopic fields or glomeruli in each
group
Table 5 Correlation with mean expression of α-SMA, vimentin, and PSGL-1 scores in the diagnostic biopsy and activity, chronicity, and
tubulointerstitial indices of the diagnostic and follow-up renal biopsy
Diagnostic biopsy Follow-up biopsy
AI CI TI AI CI TI
α-SMA in tubulointerstitium r = 0.26
p = 0.29
r = 0.27
p = 0.29
r = 0.37
p = 0.13
r = 0.35
p = 0.15
r = 0.27
p = 0.29
r = 0.55
p = 0.019
Vimentin in tubulointerstitium r = − 0.34
p = 0 .15
r = − 0.37
p = 0.12
r = – 0.27
p = 0.27
r = − 0.27
p = 0.26
r = − 0.60
p = 0.007
r = − 0.53
p = 0.019
PSGL-1 in tubulointerstitium r = 0.081
p = 0.78
r = 0.067
p = 0.82
r = 0.13
p = 0.65
r = – 0.012
p = 0.97
r = − 0.091
p = 0.76
r = − 0.044
p = 0.88
PSGL-1 in glomeruli r = − 0.10
p = 0.70
r = 0.26
p = 0.32
r = 0.06
p = 0.82
r = − 0.02
p = 0.94
r = − 0.16
p = 0.53
r = − 0.36
p = 0.15
AI, activity index; CI, chronicity index; TI, tubulointerstitial index; α-SMA, alpha-smooth muscle actin; PSGL-1, P-selectin glycoprotein ligand-1
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HSN have suggested that the chronic lesions (S1 and T1–2)
correlate with poor outcome. Xu et al. reported that segmental
glomerulosclerosis (S1) was associated with a poor renal out-
come in univariate analysis, whereas no significant associa-
tion existed with other parameters. T1 and 2 lesions were,
however, negatively associated with the risk of proteinuria
remission while other lesions showed no significant associa-
tion. Interestingly, the number of biopsies with especially E1
and T1 and 2 in the study by Xu et al. [23] differs from ours.
This may reflect inter-observer variation between pathologists
or differences in patient material and biopsy timing. T1–2 and
S1 associated with worsened renal survival also in a recent
study of 75 biopsied pediatric HSN patients [24]. In two stud-
ies with adult HSN patients, E1 also predicted outcome, with
or without S1 [25, 26]. In our study, marked differences be-
tween groups I and II occurred in C1–2 and E1 in the follow-
up biopsy, although no MEST-C parameter differed signifi-
cantly. Significant differences existed, however, in the SQC
subclasses as activity indices in both biopsies and chronicity
index in the follow-up biopsy were higher in proteinuric pa-
tients (group II) than in non-proteinuric patients (group I).
This may indicate that the evaluation of several histologic
variables together could be more advantageous than the as-
sessment of single separate variables.
Vimentin and α-SMA are markers of fibroblast activation
[27], whereas PSGL-1 is an inflammatory cell marker [28].
Vimentin and α-SMA associate with disease progression in
IgAN [29], but reports on the expression of these molecules in
HSN are scarce. Kawasaki et al. studied the expression of α-
SMA and c-MET in HSN. Hepatocyte growth factor, which
has anti-fibrogenetic effects, uses c-MET as a receptor. In the
study by Kawasaki et al., the expression of α-SMA in the first
renal biopsy correlated with the chronicity index of the second
biopsy in patients with crescents (ISKDC ≥ III) in the first
renal biopsy. c-MET showed no significant correlation with
activity or chronicity indices [18]. Our results are consistent
with those of Kawasaki et al. concerning α-SMA since in our
study, tubulointerstitial α-SMA had significant positive corre-
lation with the tubulointerstitial index—which reflects mainly
chronic changes—of the follow-up biopsy. Nonetheless, α-
SMA showed no significant correlation with the chronicity
index itself. Tubulointerstitial scores for α-SMA, vimentin,
and PSGL-1 were surprisingly higher in patients without pro-
teinuria at the follow-up biopsy, but all three markers showed
great overlap between the HSN groups (Fig. 2). We were not
able to analyze the expression of α-SMA and vimentin from
glomeruli. This was due to heavy staining, which precluded
any quantitative or semiquantitative analysis.
Our study has limitations. First, most patients had received
therapy, which had most likely altered the disease course and
possibly hampered the prognostic significance of renal biopsies
overall [30]. Second, the low number of patients with unfavor-
able outcome limits the interpretation of results from
comparison between patients with favorable and unfavorable
outcome. These two limitations are probably due to the active
treatment of severe HSN in Finland [31]. Third, histologic eval-
uation is always subject to inter-rater variability. The inter-rater
variability of SQC, assessed in our previous study, showed fair
to good reproducibility in a randomly chosen subset of ten bi-
opsies [10].
Our study has strengths. First, we were able to analyze
follow-up biopsies from patients with and without proteinuria
at the follow-up biopsy. This allowed us to evaluate the biop-
sies in relation to the patients’ clinical status. Second, data on
the feasibility of the MEST-C in pediatric HSN is scarce, and
in our study, the follow-up biopsies also underwent evaluation
withMEST-C classification. Third, the median follow-up time
in our study was 8.6 years.
Our results suggest that from diagnostic to follow-up renal
biopsy, active signs decrease and chronic signs increase re-
gardless of the clinical status, and thus follow-up biopsies
provide limited additive information to the ongoing clinical
symptoms (especially severe proteinuria) in HSN outcome
prediction. Nonetheless, all severe HSN patients, even after
a good therapeutic result, require long-term follow-up.
Compared to control specimens, HSN biopsies showed over-
expression of the pro-fibrotic and inflammatory markers, but
none were associated with prolonged proteinuria.
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